607 research outputs found
Mid-infrared optical parametric amplifier using silicon nanophotonic waveguides
All-optical signal processing is envisioned as an approach to dramatically
decrease power consumption and speed up performance of next-generation optical
telecommunications networks. Nonlinear optical effects, such as four-wave
mixing (FWM) and parametric gain, have long been explored to realize
all-optical functions in glass fibers. An alternative approach is to employ
nanoscale engineering of silicon waveguides to enhance the optical
nonlinearities by up to five orders of magnitude, enabling integrated
chip-scale all-optical signal processing. Previously, strong two-photon
absorption (TPA) of the telecom-band pump has been a fundamental and
unavoidable obstacle, limiting parametric gain to values on the order of a few
dB. Here we demonstrate a silicon nanophotonic optical parametric amplifier
exhibiting gain as large as 25.4 dB, by operating the pump in the mid-IR near
one-half the band-gap energy (E~0.55eV, lambda~2200nm), at which parasitic
TPA-related absorption vanishes. This gain is high enough to compensate all
insertion losses, resulting in 13 dB net off-chip amplification. Furthermore,
dispersion engineering dramatically increases the gain bandwidth to more than
220 nm, all realized using an ultra-compact 4 mm silicon chip. Beyond its
significant relevance to all-optical signal processing, the broadband
parametric gain also facilitates the simultaneous generation of multiple
on-chip mid-IR sources through cascaded FWM, covering a 500 nm spectral range.
Together, these results provide a foundation for the construction of
silicon-based room-temperature mid-IR light sources including tunable
chip-scale parametric oscillators, optical frequency combs, and supercontinuum
generators
Bridging the Mid-Infrared-to-Telecom Gap with Silicon Nanophotonic Spectral Translation
Expanding far beyond traditional applications in optical interconnects at
telecommunications wavelengths, the silicon nanophotonic integrated circuit
platform has recently proven its merits for working with mid-infrared (mid-IR)
optical signals in the 2-8 {\mu}m range. Mid-IR integrated optical systems are
capable of addressing applications including industrial process and
environmental monitoring, threat detection, medical diagnostics, and free-space
communication. Rapid progress has led to the demonstration of various silicon
components designed for the on-chip processing of mid-IR signals, including
waveguides, vertical grating couplers, microcavities, and electrooptic
modulators. Even so, a notable obstacle to the continued advancement of
chip-scale systems is imposed by the narrow-bandgap semiconductors, such as
InSb and HgCdTe, traditionally used to convert mid-IR photons to electrical
currents. The cryogenic or multi-stage thermo-electric cooling required to
suppress dark current noise, exponentially dependent upon the ratio Eg/kT, can
limit the development of small, low-power, and low-cost integrated optical
systems for the mid-IR. However, if the mid-IR optical signal could be
spectrally translated to shorter wavelengths, for example within the
near-infrared telecom band, photodetectors using wider bandgap semiconductors
such as InGaAs or Ge could be used to eliminate prohibitive cooling
requirements. Moreover, telecom band detectors typically perform with higher
detectivity and faster response times when compared with their mid-IR
counterparts. Here we address these challenges with a silicon-integrated
approach to spectral translation, by employing efficient four-wave mixing (FWM)
and large optical parametric gain in silicon nanophotonic wires
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immunoconjugate
molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human Factor VII
(fVII) as the targeting domain, fused to human immunoglobulin (Ig) G1 Fc as an effector domain. We evaluated hI-con1 potential
activity against primary chemotherapy-resistant USPC cell lines expressing different levels of TF.
METHODS: A total of 16 formalin-fixed, paraffin-embedded USPC samples were evaluated by immunohistochemistry (IHC) for
TF expression. Six primary USPC cell lines, half of which overexpress the epidermal growth factor type II (HER2/neu) receptor at
3\ufe levels, were assessed by flow cytometry and real-time PCR for TF expression. Sensitivity to hI-con1-dependent cell-mediated
cytotoxicity (IDCC) was evaluated in 5-hour-chromium release assays. Finally, to investigate the effect of interleukin-2 (IL-2) on
IDCC, 5-h 51Cr assays were also conducted in the presence of low doses of IL-2 (i.e., 50\u2013100 IU ml 1).
RESULTS: Cytoplasmic and/or membrane TF expression was observed in all 16 (100%) USPC samples tested by IHC, but not in normal
endometrium. High expression of TF was found in 50% (three out of six) of the USPC cell lines tested by real-time PCR and flow
cytometry when compared with normal endometrial cells (NECs; Po0.001). Uterine serous papillary adenocarcinoma cell lines
overexpressing TF, regardless of their high or low HER2/neu expression, were highly sensitive to IDCC (mean killing\ub1s.d.,
65.6\ub13.7%, range 57.5\u201377.0%, Po0.001), although negligible cytotoxicity against USPC was seen in the absence of hI-con1 or in the
presence of Rituximab control antibody. The addition of low doses of IL-2 further increased the cytotoxic effect induced by hI-con1
against chemotherapy-resistant USPC.
CONCLUSION: hI-con1 induces strong cytotoxicity against primary chemotherapy-resistant USPC cell lines overexpressing TF. The
hI-con1 may represent a novel therapeutic agent for the treatment of patients harbouring advanced, recurrent and/or metastatic
USPC refractory to standard treatment modalities
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
BACKGROUND: Uterine serous papillary carcinoma (USPC) is a biologically aggressive variant of endometrial cancer. We investigated
the expression of Serum Amyloid A (SAA) and evaluated its potential as a serum biomarker in USPC patients.
METHODS: SAA gene and protein expression levels were evaluated in USPC and normal endometrial tissues (NEC) by real-time PCR,
immunohistochemistry (IHC), flow cytometry and by a sensitive bead-based immunoassay. SAA concentration in 123 serum samples
from 51 healthy women, 42 women with benign diseases, and 30 USPC patients were also studied.
RESULTS: SAA gene expression levels were significantly higher in USPC when compared with NEC (mean copy number by
RT\u2013PCR\ubc162 vs 2.21; P\ubc0.0002). IHC revealed diffuse cytoplasmic SAA protein staining in USPC tissues. High intracellular levels
of SAA were identified in primary USPC cell lines evaluated by flow cytometry and SAA was found to be actively secreted in vitro.
SAA concentrations (mgml 1) had a median (95% CIs) of 6.0 (4.0\u20138.9) in normal healthy females and 6.0 (4.2\u20138.1) in patients with
benign disease (P\ubc0.92). In contrast, SAA values in the serum of USPC patients had a median (95% CI) of 15.6 (9.2\u201356.2),
significantly higher than those in the healthy group (P\ubc0.0005) and benign group (P\ubc0.0006). Receiver operating characteristics
(ROC) analysis of serum SAA to classify advanced- and early-stage USPC yielded an area under the ROC curve of 0.837
(P\ubc0.0024).
CONCLUSION: SAA is not only a liver-secreted protein but is also a USPC cell product. SAA may represent a novel biomarker for
USPC to assist in staging patients preoperatively, and to monitor early-disease recurrence and response to therapy
Infrared organic photodetectors employing ultralow bandgap polymer and non-fullerene acceptors for biometric monitoring
Recent efforts in the field of organic photodetectors (OPD) have been focused on extending broadband detection into the near-infrared (NIR) region. Here, two blends of an ultralow bandgap pushâpull polymer TQ-T combined with state-of-the-art non-fullerene acceptors, IEICO-4F and Y6, are compared to obtain OPDs for sensing in the NIR beyond 1100 nm, which is the cut off for benchmark Si photodiodes. It is observed that the TQ-T:IEICO-4F device has a superior IR responsivity (0.03 AW-1 at 1200 nm and â2 V bias) and can detect infrared light up to 1800 nm, while the TQ-T:Y6 blend shows a lower responsivity of 0.01 AW-1. Device physics analyses are tied with spectroscopic and morphological studies to link the superior performance of TQ-T:IEICO-4F OPD to its faster charge separation as well as more favorable donorâacceptor domains mixing. In the polymer blend with Y6, the formation of large agglomerates that exceed the exciton diffusion length, which leads to high charge recombination, is observed. An application of these devices as biometric sensors for real-time heart rate monitoring via photoplethysmography, utilizing infrared light, is demonstrated
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
Type II endometrial cancers (uterine serous papillary and clear cell histologies) represent rare but highly aggressive variants of endometrial cancer (EC). HER2 and EGFR may be differentially expressed in type II EC. Here, we evaluate the clinical role of HER2 and EGFR in a large cohort of surgically staged patients with type II (nonendometrioid) EC and compare the findings with those seen in a representative cohort of type I (endometrioid) EC. In this study HER2 gene amplification was studied by fluorescence in situ hybridisation (FISH) and EGFR expression by immunohistochemistry. Tissue microarrays were constructed from 279 patients with EC (145 patients with type I and 134 patients with type II EC). All patients were completely surgically staged and long-term clinical follow up was available for 258 patients. The rate of HER2 gene amplification was significantly higher in type II EC compared with type I EC (17 vs 1%, P<0.001). HER2 gene amplification was detected in 17 and 16% of the cases with uterine serous papillary and clear cell type histology, respectively. In contrast, EGFR expression was significantly lower in type II compared with type I EC (34 vs 46%, P=0.041). EGFR expression but not HER2 gene amplification was significantly associated with poor overall survival in patients with type II EC, (EGFR, median survival 20 vs 33 months, P=0.028; HER2, median survival 18 vs 29 months, P=0.113) and EGFR expression retained prognostic independence when adjusting for histology, stage, grade, and age (EGFR, P=0.0197; HER2, P=0.7855). We conclude that assessment of HER2 gene amplification and/or EGFR expression may help to select type II EC patients who could benefit from therapeutic strategies targeting both HER2 and EGFR
Search for direct pair production of the top squark in all-hadronic final states in proton-proton collisions at sâ=8 TeV with the ATLAS detector
The results of a search for direct pair production of the scalar partner to the top quark using an integrated luminosity of 20.1fbâ1 of protonâproton collision data at âs = 8 TeV recorded with the ATLAS detector at the LHC are reported. The top squark is assumed to decay via tËâtÏË01 or tËâ bÏ˱1 âbW(â)ÏË01 , where ÏË01 (Ï˱1 ) denotes the lightest neutralino (chargino) in supersymmetric models. The search targets a fully-hadronic final state in events with four or more jets and large missing transverse momentum. No significant excess over the Standard Model background prediction is observed, and exclusion limits are reported in terms of the top squark and neutralino masses and as a function of the branching fraction of tË â tÏË01 . For a branching fraction of 100%, top squark masses in the range 270â645 GeV are excluded for ÏË01 masses below 30 GeV. For a branching fraction of 50% to either tË â tÏË01 or tË â bÏ˱1 , and assuming the Ï˱1 mass to be twice the ÏË01 mass, top squark masses in the range 250â550 GeV are excluded for ÏË01 masses below 60 GeV
Search for pair-produced long-lived neutral particles decaying to jets in the ATLAS hadronic calorimeter in ppcollisions at âs=8TeV
The ATLAS detector at the Large Hadron Collider at CERN is used to search for the decay of a scalar boson to a pair of long-lived particles, neutral under the Standard Model gauge group, in 20.3fbâ1of data collected in protonâproton collisions at âs=8TeV. This search is sensitive to long-lived particles that decay to Standard Model particles producing jets at the outer edge of the ATLAS electromagnetic calorimeter or inside the hadronic calorimeter. No significant excess of events is observed. Limits are reported on the product of the scalar boson production cross section times branching ratio into long-lived neutral particles as a function of the proper lifetime of the particles. Limits are reported for boson masses from 100 GeVto 900 GeV, and a long-lived neutral particle mass from 10 GeVto 150 GeV
Measurement of the cross-section of high transverse momentum vector bosons reconstructed as single jets and studies of jet substructure in pp collisions at âs = 7 TeV with the ATLAS detector
This paper presents a measurement of the cross-section for high transverse momentum W and Z bosons produced in pp collisions and decaying to all-hadronic final states. The data used in the analysis were recorded by the ATLAS detector at the CERN Large Hadron Collider at a centre-of-mass energy of âs = 7 TeV;{\rm Te}{\rm V}4.6\;{\rm f}{{{\rm b}}^{-1}}{{p}_{{\rm T}}}\gt 320\;{\rm Ge}{\rm V}|\eta |\lt 1.9{{\sigma }_{W+Z}}=8.5\pm 1.7$ pb and is compared to next-to-leading-order calculations. The selected events are further used to study jet grooming techniques
- âŠ